<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386880</url>
  </required_header>
  <id_info>
    <org_study_id>AA-Phono-CA</org_study_id>
    <nct_id>NCT00386880</nct_id>
  </id_info>
  <brief_title>Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs</brief_title>
  <official_title>Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has
      been noted in several studies that in patients with migraine, seventy nine percent of the
      patients experienced allodynia on the facial skin on the same side as the headache.
      Understanding more about the occurrence of phonophobia (increased sensitivity to sound) and
      allodynia may help us understand how the pain system works in migraine. It is hoped that the
      knowledge gained from this trial may enable us to more effectively treat patients with
      migraine headache.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between Phonophobia (Sound Sensitivity) and Allodynia (Skin Sensitivity) in Subjects With Episodic Migraine</measure>
    <time_frame>Subjects with or without allodynia return during a migraine attack and are tested for Phonophobia.</time_frame>
    <description>Measurement of phonophobia: determine sound aversion threshold (SAT), measured in dB during a migraine attack in subjects with and in subjects without allodynia.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Subjects with episodic migraine with allodynia</arm_group_label>
    <description>These are subjects with episodic migraine with allodynia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with episodic migraine without allodynia</arm_group_label>
    <description>Subjects with episodic migraine without allodynia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sounds</intervention_name>
    <arm_group_label>Subjects with episodic migraine with allodynia</arm_group_label>
    <arm_group_label>Subjects with episodic migraine without allodynia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women and men with a diagnosis of episodic migraine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for migraine subjects:

          -  Age: 18 - 65 years, inclusive.

          -  Gender: male or female

          -  Diagnosis: Episodic migraine with or without aura, as defined by the International
             Headache Society (IHS), for at least 6 months prior to enrollment.

          -  An average of â‰¥1 migraine attack per month over the 6-month period prior to
             enrollment.

          -  An average of &lt;15 headache (of any type) days per month for the 6 months prior to
             enrollment.

          -  Normal audiogram. (A hearing threshold of 20 dB or less at the frequency range of
             200-8000Hz.).

        Inclusion criteria for control subjects:

          -  Age: 18 - 65 years, inclusive.

          -  Gender: male or female

          -  Non-headache sufferers with the exception of infrequent ETTH according to IHS criteria
             (lifetime occurrence of at least 10 episodes occurring on &lt;1 day per month on average
             and &lt;12 days per year)

          -  Normal audiogram, (A hearing threshold of 20 dB or less at the frequency range of
             200-8000Hz.).

        Exclusion criteria for migraine subjects:

          -  Any other headache diagnosis (e.g. cluster headache, hemicrania continua, post
             traumatic headache, etc.) except for episodic tension type headache (ETTH) with an
             average of no more than 10 ETTH headache days per month for the 6 months prior to
             enrollment (note: average &lt;15 total HA days is specified in inclusion)

          -  Use of any headache preventive drug (determined by investigator) in the 90 days prior
             to screening.

          -  Treatment with botulinum toxin (for any indication) within the 90 day period prior to
             enrollment.

          -  Treatment with occipital nerve block or block, or block of any other nerve in the head
             or neck area, within the 30 day period prior to enrollment.

          -  Any dermatological disease that may affect skin sensation.

          -  Any neurological disease that may affect sensory functions (e.g stroke, multiple
             sclerosis, peripheral neuropathy).

          -  Cognitive disturbance that may affect the subject's ability to understand the study
             procedure.

          -  Significant psychiatric disturbance that may impair the subject from co-operating with
             the study procedures.

          -  Use of acute pain medications on a daily or frequent pattern (for any indication) as
             defined by the IHS.

        Exclusion criteria for control subjects:

          -  Any other headache diagnosis except for IHS-defined infrequent ETTH.

          -  Use of any headache preventive drug (determined by investigator) in the 90 days prior
             to screening.

          -  Treatment with botulinum toxin (for any indication) within the 90 day period prior to
             enrollment.

          -  Treatment with occipital nerve block or block, or block of any other nerve in the head
             or neck area, within the 30 day period prior to enrollment.

          -  Any dermatological disease that may affect skin sensation.

          -  Any neurological disease that may affect sensory functions (e.g stroke, multiple
             sclerosis, peripheral neuropathy).

          -  Cognitive disturbance that may affect the subject's ability to understand the study
             procedure.

          -  Significant psychiatric disturbance that may impair the subject from co-operating with
             the study procedures.

          -  Use of acute pain medications on a daily or frequent pattern (for any indication) as
             defined by the IHS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham A. Ashkenazi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson Headache Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ashkenazi A, Yang I, Mushtaq A, Oshinsky ML. Is phonophobia associated with cutaneous allodynia in migraine? J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1256-60. doi: 10.1136/jnnp.2009.198481. Epub 2010 Jun 20.</citation>
    <PMID>20562466</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2006</study_first_posted>
  <results_first_submitted>August 5, 2012</results_first_submitted>
  <results_first_submitted_qc>August 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Hyperacusis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Episodic Migraine With Allodynia</title>
          <description>These are the subjects with episodic migraine with allodynia.</description>
        </group>
        <group group_id="P2">
          <title>Subjects With Episodic Migraine Without Allodynia</title>
          <description>These are the subjects with episodic migraine without allodynia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Episodic Migraine</title>
          <description>Subjects with less than 8 distict migraine episodes per month.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Phonophobia (Sound Sensitivity) and Allodynia (Skin Sensitivity) in Subjects With Episodic Migraine</title>
        <description>Measurement of phonophobia: determine sound aversion threshold (SAT), measured in dB during a migraine attack in subjects with and in subjects without allodynia.</description>
        <time_frame>Subjects with or without allodynia return during a migraine attack and are tested for Phonophobia.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Episodic Migraine With Allodynia</title>
            <description>These are subjects with episodic migraine with allodynia</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Episodic Migraine Without Allodynia</title>
            <description>These are subjects with episodic migraine without allodynia</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Phonophobia (Sound Sensitivity) and Allodynia (Skin Sensitivity) in Subjects With Episodic Migraine</title>
          <description>Measurement of phonophobia: determine sound aversion threshold (SAT), measured in dB during a migraine attack in subjects with and in subjects without allodynia.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the acute migraine attack, 90% of allodynic subjects and 75% of subjects without allodynia had phonophobia.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Episodic Migraine</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abraham A. Ashkenazi, MD-Principal Investigator</name_or_title>
      <organization>Doylestown Hospital</organization>
      <phone>215-625-2894</phone>
      <email>aashkenazi2001@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

